Clinical Research Directory

Browse clinical research sites, groups, and studies.

1 clinical study listed.

Healthy volunteers

Filters:

Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies

Tundra lists 1 Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies clinical trial. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07051070

Efficacy and Safety of Rituximab in the Treatment of Anti-Vimentin Antibody-associated Diseases

In 2025, a novel meningoencephalomyelitis associated with Vimentin IgG in cerebrospinal fluid (CSF) has been identified. Most patients exhibited progressive or recurrent episodes, characterized by prominent cerebellar ataxia, cranial nerve palsies, and pyramidal signs. The characteristic features included bilateral magnetic resonance imaging (MRI) lesions of the corticospinal tract, elevated CSF protein levels, and increased CSF cell counts. Despite receiving immunotherapy, these patients experienced significant disability. This study employed a single-center, open-label, single-arm design to investigate the clinical efficacy and safety of rituximab (RTX) treatment in 40 patients with vimentin antibody (VIMA)-related diseases.

Gender: All

Ages: 18 Years - Any

Updated: 2025-07-03

Anti-Vimentin Antibody-associated Diseases

Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies